Literature DB >> 11966858

What do patients with migraine want from acute migraine treatment?

Richard B Lipton1, Sandra W Hamelsky, Jeffrey M Dayno.   

Abstract

Migraine is a common chronic condition with an ever-expanding therapeutic armamentarium. As therapeutic options multiply, it is increasingly important to understand patients' attitudes and preferences regarding various treatment characteristics. Several strategies have evolved to establish treatment priorities in migraine and rationalize and prioritize end points and outcomes to meet the needs of patients. A survey of a population-based sample of migraineurs indicated that an overwhelming majority of patients consider complete relief of head pain, no recurrence, and rapid onset of action as important or very important attributes of acute migraine therapy. An analysis of the relationship between clinical end points and satisfaction found that more than 90% of patients who were pain-free at 2 hours were at least somewhat satisfied with treatment, but satisfaction was dependent on relatively rapid relief. Using a "willingness-to-pay" approach, results indicated that while patients will pay more for migraine treatment that produces rapid, consistent relief without adverse effects or recurrence, speed of complete relief is the most valued attribute. By assessing physician preferences and practices, degree of pain relief and rapid onset were identified as the most important attributes of acute therapy. Based on results from preference studies of triptans, 50% of patients cited more rapid pain relief as the most important determinant of treatment preference. Based on these various approaches, the consensus view is that both clinicians and patients desire a broad range of positive migraine treatment attributes, but rapid onset of complete pain relief is a particularly important priority.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11966858     DOI: 10.1046/j.1526-4610.2002.0420s1003.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  52 in total

Review 1.  Taking the negative view of current migraine treatments: the unmet needs.

Authors:  Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

2.  Placebo response in migraine.

Authors:  Peer Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  2010-11-23       Impact factor: 2.953

3.  Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.

Authors:  Hans-Christoph Diener; Stefan Evers
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

4.  Pain freedom at 2 hours in migraine after telcagepant 300 mg.

Authors:  Peer Tfelt-Hansen
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

5.  Low efficacy of transdermal sumatriptan in migraine.

Authors:  Peer Tfelt-Hansen
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

Review 6.  Meeting acute migraine treatment needs through novel treatment formulations.

Authors:  Stephen D Silberstein
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

7.  Adherence to headache treatment and profile of previous health professional seeking among patients with chronic headache: a retrospective analysis.

Authors:  Abouch Valenty Krymchantowski; Marcus Vinicius Adriano; Renemilda de Góes; Pedro Ferreira Moreira; Carla da Cunha Jevoux
Journal:  MedGenMed       Date:  2007-04-26

8.  Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes.

Authors:  Stephen Landy; Sarah E DeRossett; Alan Rapoport; John Rothrock; Michael H Ames; Susan A McDonald; Steven P Burch
Journal:  MedGenMed       Date:  2007-06-07

9.  Standardizing emergency department-based migraine research: an analysis of commonly used clinical trial outcome measures.

Authors:  Benjamin W Friedman; Polly E Bijur; Richard B Lipton
Journal:  Acad Emerg Med       Date:  2010-01       Impact factor: 3.451

10.  Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan.

Authors:  L C Newman; R K Cady; S Landy; P O'Carroll; W J Kwong; S P Burch; A C Nelsen; S A McDonald
Journal:  Int J Clin Pract       Date:  2008-12       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.